EGTA AM (Synonyms: EGTA Acetoxymethyl ester) |
Catalog No.GC43589
One-Click Copy Product Info
|
EGTA AM은 느린 킬레이트 역학을 가진 막 투과성 Ca²⁺ 킬레이터이다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 99590-86-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
EGTA AM은 느린 킬레이트 역학을 가진 막 투과성 Ca²⁺ 킬레이터이다. EGTA AM은 욕액 적용에 의해 세포 내로 로딩될 수 있어 글루타메이트의 비동기적 방출을 유발하기 위해 필요한 Ca²⁺의 느린 상승을 차단할 수 있다[1]. EGTA AM에 의한 칼슘 킬레이션은 투명대에 의해 유도된 정자방출반응과 세포 사멸을 억제하고 정자 운동성을 증가시킨다[2]. EGTA AM은 칼슘 이온을 킬레이트화하고 융합해서 잡종 세포소기관을 형성하는 것을 억제할 수 있다[3]. EGTA AM은 낮은 농도에서 알츠하이머병 뇌 조직 시료의 아밀로이드 플라크를 효과적으로 용해할 수 있다[4]. EGTA AM은 호흡기 점액의 물리화학적 특성을 변화시켜 항M1 단클론 항체와 반응하는 에피토프를 노출해서 M1/MUC5AC 점액의 검출을 촉진한다[5]. EGTA AM은 유해한 산화환원 활성 금속 이온에 결합할 수 있고 활성 산소 및 질소 물질을 해독할 수 있어 촉매 항산화제의 개발에 도움이 된다[6].
References:
[1] Li M J, Chang T W, Hung W C, et al. Cholinergic and glutamatergic transmission at synapses between pedunculopotine tegmental nucleus axonal terminals and A7 catecholamine cell group noradrenergic neurons in the rat[J]. Neuropharmacology, 2016, 110: 237-250.
[2] Ebrahimi B, Keshtgar S. The effects of EGTA on the quality of fresh and cryopreserved-thawed human spermatozoa[J]. Iranian Journal of Medical Sciences, 2020, 45(3): 188.
[3] Pryor P R, Mullock B M, Bright N A, et al. The role of intraorganellar Ca2+ in late endosome–lysosome heterotypic fusion and in the reformation of lysosomes from hybrid organelles[J]. The Journal of cell biology, 2000, 149(5): 1053-1062.
[4] Cherny R A, Legg J T, McLean C A, et al. Aqueous dissolution of Alzheimer's disease Aβ amyloid deposits by biometal depletion[J]. Journal of Biological Chemistry, 1999, 274(33): 23223-23228.
[5] Roger P, Gascard J P, Bara J, et al. EGTA treatment of human airways in vitro unmasks M1/MUC5AC mucin in submucosal glands[J]. European Respiratory Journal, 2001, 18(1): 176-183.
[6] Fisher A E O, Hague T A, Clarke C L, et al. Catalytic superoxide scavenging by metal complexes of the calcium chelator EGTA and contrast agent EHPG[J]. Biochemical and biophysical research communications, 2004, 323(1): 163-167.
| Cas No. | 99590-86-0 | SDF | |
| Synonyms | EGTA Acetoxymethyl ester | ||
| Canonical SMILES | CC(OCOC(CN(CC(OCOC(C)=O)=O)CCOCCOCCN(CC(OCOC(C)=O)=O)CC(OCOC(C)=O)=O)=O)=O | ||
| Formula | C26H40N2O18 | M.Wt | 668.6 |
| Solubility | DMSO : 100 mg/mL (149.57 mM; ultrasonic and warming and heat to 60°C) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.4957 mL | 7.4783 mL | 14.9566 mL |
| 5 mM | 299.1 μL | 1.4957 mL | 2.9913 mL |
| 10 mM | 149.6 μL | 747.8 μL | 1.4957 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >95.00% Appearance: A liquid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 10 reference(s) in Google Scholar.)